The first results of phase IIA of clinical studies of photodynamic therapy for subretinal neovascular membranes with photosense

The subretinal neovascular membrane (SNM) is a common complication of diseases, such as senile macular degeneration, myopia, pseudohistoplasmic syndrome, and many others. There is no algorithm of treatment for this pathology in today's ophthalmological care; however, many authors have arrived a...

Full description

Saved in:
Bibliographic Details
Published inVestnik oftal'mologii Vol. 121; no. 5; p. 6
Main Authors Avetisov, S E, Budzinskaia, M V, Likhvantseva, V G, Gurova, I V, Loshchenov, V B, Shevchik, S A, Kuz'min, S G, Vorozhtsov, G N
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.09.2005
Subjects
Adult
Aged
Follow-Up Studies
Humans
Indoles - therapeutic use
Macular Degeneration - complications
Middle Aged
Myopia - complications
Organometallic Compounds - therapeutic use
Photochemotherapy
Photosensitizing Agents - administration & dosage
Photosensitizing Agents - therapeutic use
Prospective Studies
Retinal Neovascularization - drug therapy
Time Factors
Online AccessGet more information

Cover

More Information
Summary:The subretinal neovascular membrane (SNM) is a common complication of diseases, such as senile macular degeneration, myopia, pseudohistoplasmic syndrome, and many others. There is no algorithm of treatment for this pathology in today's ophthalmological care; however, many authors have arrived at the conclusion that photodynamic therapy (PDT) plays a major role in solving this difficult problem. Fifteen (18 eyes) patients, including 8 (8 eyes) patients diagnosed as having senile macular degeneration and SNM and 7 (10 eyes) patients diagnosed as having complicated high-grade myopia, and 3 were diagnosed as having bilateral SNM. The Russian agent Photosense, 0.05 mg/kg, was used as a photosensitizer. PDT was performed on day 3 after administration of the agent according to the peak of accumulation and the maximum laser concentration gradient at a wavelength of 675 nm and a light dose of 120 J/cm2. Good functional and angiographic results may be observed after the first 3 months of a prospective controlled open-labeled study of the efficiency of PDT with Photosense; however, longer follow-ups and larger groups of patients are required to make a final assessment of this treatment.
ISSN:0042-465X